| |
J&J Letter to HIV Community
|
| |
| |
Dear Advocacy Partner:
I hope this note finds you safe and well in these difficult times.
As we face this global health crisis together, please know that all of us here at Johnson & Johnson (J&J) are mobilized to ensure we are meeting the needs of our patients, customers, partners, employees and communities. Aligned with Our Credo, we are taking action to help prevent the spread of the coronavirus (COVID-19), exploring the potential for a vaccine, and executing robust business continuity plans across our global supply chain networks to support those who rely on our products - including people living with HIV who depend on darunavir. In this letter, I would like to share some important updates on our supply chain and the use of darunavir in treating COVID-19.
Supply Chain Status
While the situation remains dynamic, we do not foresee pharmaceutical supply interruptions due to COVID-19 at this time. We want to assure you that we are closely monitoring product demand and supply levels across our global network, maintaining critical inventory at major distribution centers away from high-risk areas and working with external suppliers to support our preparedness plans. To further manage supply levels, we are also asking customers to maintain their normal ordering patterns at this time.
Lack of Evidence to Support the Use of Darunavir-based Treatments for COVID-19
You may have heard reports that despite a lack of published evidence, darunavir is being considered as a therapeutic option for COVID-19. As an update, we now have both in vitro and in vivo evidence that darunavir is NOT an effective treatment for coronavirus. We are working to publish and communicate this information broadly so that patients diagnosed with COVID-19 receive a treatment that shows more promise, and so people who count on darunavir-based medicines continue to have access to them.
There is no higher priority than patient health for Janssen and J&J. We are committed to doing everything we can to help address this global crisis, including leveraging our deep scientific expertise and extensive partnerships to take on this challenge and address critical needs.
To stay up to date on our COVID-19 efforts, you can visit www.jnj.com/coronavirus. For information specifically related to our supply and business continuity plans, you can visit: https://www.jnj.com/j-j-business-continuity-statement.
If you have any questions, please don’t hesitate to reach out. We appreciate all you do for the community - especially during times like these.
Be well,
Marcus A. Wilson
National Policy & Advocacy Director
Health Care Systems, Inc.
Privacy Policy www.janssen.com/us/privacy-policy
The information in this e-mail may be privileged and confidential, intended only for the use of the addressee above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender. Please let the sender know if you no longer wish to receive email updates on news of this nature.
Janssen Therapeutics, Division of Janssen Products, LP
1125 Trenton-Harbourton Road
Titusville, NJ 08560
|
|
| |
| |
|
|
|
